Assessment of Nurses’ Knowledge Regarding Adverse Effect Of Antihypertensive Drugs: A Cross Sectional Study
-
(1) * Wasfi dhahir Abid Ali
Iraq
(*) Corresponding Author
Abstract
The current study was conducted in some hospitals in Basra, southern Iraq, on some nurses working in various departments to participate in the questionnaire, which aims to evaluate nurses’ knowledge about the adverse action of high blood pressure medications. 70 female and male nurses participated in the questionnaire to answer 20 questions. The results were 78. 49% of the nurses were sure of the answer, 20% did not know the answer, and 25.9 were not sure of their answers The total mean of score was significant (2.27),. The results conclude that knowledge of nurses regarding the adverse effects of high blood pressure medications on patients is insufficient, and nurses need to enhance scientific and practical knowledge.
References
Abimbola O. Olowofela and Ambrose O. Isah.A Profile of Adverse Effects of
Antihypertensive Medicines in a Tertiary Care Clinic in NigeriaAnn Afr Med. 2017 Jul-Sep; 16(3): 114–119.
Atiyah M. Nurses’ Knowledge Regarding Management of Hypovolemic Shock: A Cross-Sectional Study. acopen [Internet]. 2024May12 [cited 2024Jun.7];9(2):DOI 10.21070/acopen.9.2024.8925.
Aubert, B. A., Barki, H., Patry, M., & Roy, V. A multi‐level, multi‐theory perspective of information technology implementation. Information Systems Journal,2008, 18(1), 45-72.
Bardage C, Isacson DG. Self-reported side-effects of antihypertensive drugs: an epidemiological study on prevalence and impact on health-state utility. Blood Press. 2000;9(6):328–34.
Bashyal, S. P., & Thapa, N.). Knowledge and perception regarding hypertension among hypertensive patients at a tertiary hospital in Kathmandu, Nepal. Journal of Advanced Academic Research,2020, 7(1), 51-62.
Black H, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11(8):483–9.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–71.
Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.
Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253(22):3263–8.
Cushman WCBlack HR Hypertension in the elderly. Cardiol Clin. 1999;1779- 92.
Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418–25.
Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press. 1998;7(5–6):313–5.
Flack JMYunis CPreisser J et al. ATIME Research Group, The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. Arch Intern Med. 2000;1601842- 1847.
Fletcher AE, Bulpitt CJ, Chase DM, Collins WC, Furberg CD, Goggin TK, et al. Quality of life with three antihypertensive treatments. Cilazapril Atenolol Nifedipine Hypertension. 1992;19(6 Pt 1):499–507.
Frey L, Gravestock I, Pichierri G, Steurer J, Burgstaller J Serious adverse events in patients with target-oriented blood pressure management: a systematic review. J Hypertens2019;37:2135-44.
Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556–64.
Gebreyohannes, E.A., Bhagavathula, A.S., Abebe, T.B. et al. Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital. Clin Hypertens 25, 1 (2019). https://doi.org/10.1186/s40885-018-0104-6.
Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992;117(3):234–42.
Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14(3):181–8.
Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother. 2005;39(7–8):1198–203.
MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193–217.
MacConnachie AMMaclean D Low dose combination antihypertensive therapy: additional without additional adverse effects? Drug Safety. 1995;1285- 90.
Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002;4(6):479–82.
Monane MBohn RLGurwitz JH et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10 ((pt 1)) 697- 704.
Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499–509.
Olowofela AO, Isah AO. A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria. Ann Afr Med. 2017 Jul-Sep;16(3):114-119. doi: 10.4103/aam.aam_6_17. PMID: 28671151; PMCID: PMC5579894.
Olsen H, klemetsrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press. 1999;8(2):94–101.
Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150(8):1707–13.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens2016;34:1921-32. . doi:10.1097/HJH.0000000000001052 pmid:27454050.
Tomasović, S., Sremec, J., Košćak, J., Klepac, N., Draganić, P., & Bielen, I. Epidemiological characteristics of dementia treatment in Croatia. Psychiatria Danubina,2016, 28(2), 170-175.
World Health Organization. A global brief on hypertension: silent killer, global public health crisis. 2013. Availab from: https://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/.
World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. 2007 Availablefrom: http://apps.who.int/iris/bitstream/handle/10665/43685/9789241547178_eng.pdf;jsessionid=26CDD2C8C638CCBD9CD27371D22A1F3C?sequence=1
Antihypertensive Medicines in a Tertiary Care Clinic in NigeriaAnn Afr Med. 2017 Jul-Sep; 16(3): 114–119.
Atiyah M. Nurses’ Knowledge Regarding Management of Hypovolemic Shock: A Cross-Sectional Study. acopen [Internet]. 2024May12 [cited 2024Jun.7];9(2):DOI 10.21070/acopen.9.2024.8925.
Aubert, B. A., Barki, H., Patry, M., & Roy, V. A multi‐level, multi‐theory perspective of information technology implementation. Information Systems Journal,2008, 18(1), 45-72.
Bardage C, Isacson DG. Self-reported side-effects of antihypertensive drugs: an epidemiological study on prevalence and impact on health-state utility. Blood Press. 2000;9(6):328–34.
Bashyal, S. P., & Thapa, N.). Knowledge and perception regarding hypertension among hypertensive patients at a tertiary hospital in Kathmandu, Nepal. Journal of Advanced Academic Research,2020, 7(1), 51-62.
Black H, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11(8):483–9.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–71.
Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.
Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253(22):3263–8.
Cushman WCBlack HR Hypertension in the elderly. Cardiol Clin. 1999;1779- 92.
Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418–25.
Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press. 1998;7(5–6):313–5.
Flack JMYunis CPreisser J et al. ATIME Research Group, The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. Arch Intern Med. 2000;1601842- 1847.
Fletcher AE, Bulpitt CJ, Chase DM, Collins WC, Furberg CD, Goggin TK, et al. Quality of life with three antihypertensive treatments. Cilazapril Atenolol Nifedipine Hypertension. 1992;19(6 Pt 1):499–507.
Frey L, Gravestock I, Pichierri G, Steurer J, Burgstaller J Serious adverse events in patients with target-oriented blood pressure management: a systematic review. J Hypertens2019;37:2135-44.
Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556–64.
Gebreyohannes, E.A., Bhagavathula, A.S., Abebe, T.B. et al. Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital. Clin Hypertens 25, 1 (2019). https://doi.org/10.1186/s40885-018-0104-6.
Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992;117(3):234–42.
Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14(3):181–8.
Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother. 2005;39(7–8):1198–203.
MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193–217.
MacConnachie AMMaclean D Low dose combination antihypertensive therapy: additional without additional adverse effects? Drug Safety. 1995;1285- 90.
Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002;4(6):479–82.
Monane MBohn RLGurwitz JH et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10 ((pt 1)) 697- 704.
Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499–509.
Olowofela AO, Isah AO. A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria. Ann Afr Med. 2017 Jul-Sep;16(3):114-119. doi: 10.4103/aam.aam_6_17. PMID: 28671151; PMCID: PMC5579894.
Olsen H, klemetsrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press. 1999;8(2):94–101.
Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150(8):1707–13.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens2016;34:1921-32. . doi:10.1097/HJH.0000000000001052 pmid:27454050.
Tomasović, S., Sremec, J., Košćak, J., Klepac, N., Draganić, P., & Bielen, I. Epidemiological characteristics of dementia treatment in Croatia. Psychiatria Danubina,2016, 28(2), 170-175.
World Health Organization. A global brief on hypertension: silent killer, global public health crisis. 2013. Availab from: https://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/.
World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. 2007 Availablefrom: http://apps.who.int/iris/bitstream/handle/10665/43685/9789241547178_eng.pdf;jsessionid=26CDD2C8C638CCBD9CD27371D22A1F3C?sequence=1
Picture in here are illustration from public domain image (License) or provided by the author, as part of their works
Published
2024-07-30
Issue
Section
Articles
Copyright (c) 2024 Wasfi dhahir Abid Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
